Orion - Company Announcement

Decision by the Board of Directors to acquire own shares

ORION CORPORATION        STOCK EXCHANGE RELEASE 23 APRIL 2013 at 1.00  PM EEST


The Board of Directors of Orion Corporation decided on 23 April 2013 on a share
acquisition based on the authorisation by the Annual General Meeting on 19 March
2013. According to the decision, 500,000 Class B shares of Orion Corporation
will be acquired. The acquisition will be started at the earliest on 2 May 2013
and it can continue until further notice. The acquisition of the shares will be
executed in accordance with the terms of the authorisation by the Annual General
Meeting.
The shares shall be acquired using funds in the company's distributable equity
at the price of the acquisition moment quoted at trading on regulated market
organised by NASDAQ OMX Helsinki Oy ("Stock Exchange"), in proportions not
corresponding to the shareholders' holdings. The shares shall be acquired and
paid for in accordance with the rules of the Stock Exchange and Euroclear
Finland Ltd.

The shares will be acquired to be used as part of the execution of the long-term
Incentive Plan 2013 for key persons of the Orion Group. There is a weighty
financial reason for the targeted share acquisition, because the purpose of the
incentive plan is to encourage the persons involved in it to sustained
commitment and efforts for the benefit of the company and its shareholders.

The terms and conditions of the authorisation to acquire the company's own
shares are attached to this release. They were published in the stock exchange
release of 19 March 2013 concerning the decisions of the Annual General Meeting
of Orion Corporation.

The 2012 Financial Statements documents of Orion Corporation, the decision of
the profit distribution made by the Annual General Meeting on 19 March 2013 as
well as the Interim Report 1-3/2013 are available on the homepage
http://www.orion.fi/en/News-and-media/, as provided in the Companies Act.


Orion Corporation



 Timo Lappalainen    Olli Huotari
 President and CEO   SVP, Corporate Functions





Contact person:
Olli Huotari, SVP, Corporate Functions
tel. +358 10 426 3054







APPENDIX:

Authorisation of  the Board of Directors to decide on acquisition
of the company's own shares

The Board of Directors of Orion Corporation was authorised by the Annual General
Meeting 2013 of Orion Corporation to decide on the acquisition of the company's
own shares on the following terms and conditions:

Maximum amount of shares to be acquired
On the basis of the authorisation, the Board of Directors shall be entitled to
decide on the acquisition of no more than 500,000 B-shares of Orion Corporation.

Consideration to be paid for the shares
The own shares shall be acquired at the price of the acquisition moment quoted
at trading on regulated market organised by NASDAQ OMX Helsinki Ltd ("Stock
Exchange"), using funds in the Company's distributable equity.

Targeted acquisition
The own shares shall be acquired through trading on regulated market organised
by the Stock Exchange in a proportion not corresponding to the shareholders'
holdings. The shares shall be acquired and paid for in accordance with the rules
of the Stock Exchange and Euroclear Finland Ltd.

Holding, invalidation and conveyance of the shares
The shares acquired can be kept, invalidated, or further conveyed by the
Company.

The shares can be acquired for the purpose of developing the capital structure
of the Company, for using them for financing possible corporate acquisitions or
other business arrangements of the Company, for financing capital expenditure,
as part of the Company's incentive system, or otherwise conveying or
invalidating them.

Other terms and validity
The Board of Directors shall decide on other matters related to the acquisition
of own shares.

The authorisation to acquire own shares shall be valid 18 months from the
decision of the Annual General Meeting of the Shareholders.




Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2012 amounted to EUR 980 million and the company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

[HUG#1695294]